Journal of Psychopharmacology · 2015 · 376 citations · 40 references
NursingPsychiatryPsychologyBehavioral HealthSubstance Use DisordersSuicide PreventionAddictionDrugs Of AbusePsychiatric EpidemiologySubstance UseDrug Use EpidemiologyMental Health ImpactsOdds Ratio ModelingPredictors Of Suicide RiskPsychedelic Drug UseSubstance Use EpidemiologySuicidal RiskSuicide Attempt Risk
Mental health problems are widespread worldwide, with suicide a leading cause of death, and while classic psychedelic use may improve mental health, its impact on suicidality remains unclear. The study examined how classic psychedelic use relates to psychological distress and suicidality in over 190,000 U.S. adults, adjusting for multiple covariates. Using pooled data from the 2008–2012 National Survey on Drug Use and Health, the authors assessed these associations while controlling for a range of covariates.
Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over 190,000 USA adult respondents pooled from the last five available years of the National Survey on Drug Use and Health (2008-2012) while controlling for a range of covariates. Lifetime classic psychedelic use was associated with a significantly reduced odds of past month psychological distress (weighted odds ratio (OR)=0.81 (0.72-0.91)), past year suicidal thinking (weighted OR=0.86 (0.78-0.94)), past year suicidal planning (weighted OR=0.71 (0.54-0.94)), and past year suicide attempt (weighted OR=0.64 (0.46-0.89)), whereas lifetime illicit use of other drugs was largely associated with an increased likelihood of these outcomes. These findings indicate that classic psychedelics may hold promise in the prevention of suicide, supporting the view that classic psychedelics' most highly restricted legal status should be reconsidered to facilitate scientific study, and suggesting that more extensive clinical research with classic psychedelics is warranted.
40
Drug harms in the UK: a multicriteria decision analysis
David Nutt, Leslie A. King, Lawrence D. Phillips · The Lancet · 2010 · 1.7K citations